Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study

por Leighl, N B, Bennouna, J, Yi, J, Moore, N, Hambleton, J, Hurwitz, H
Publicado 2011

Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer

por Pallis, A G, Fennell, D A, Szutowicz, E, Leighl, N B, Greillier, L, Dziadziuszko, R
Publicado 2011

Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer

por Leighl, N B, Shepherd, F A, Zawisza, D, Burkes, R L, Feld, R, Waldron, J, Sun, A, Payne, D, Bezjak, A, Tattersall, M H N
Publicado 2008

Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation

por Gosney, J.R., Paz-Ares, L., Jänne, P., Kerr, K.M., Leighl, N.B., Lozano, M.D., Malapelle, U., Mok, T., Sheffield, B.S., Tufman, A., Wistuba, I.I., Peters, S.
Publicado 2023

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell l...

por Chen, H, Modiano, M R, Neal, J W, Brahmer, J R, Rigas, J R, Jotte, R M, Leighl, N B, Riess, J W, Kuo, C J, Liu, L, Gao, B, DiCioccio, A T, Adjei, A A, Wakelee, H A
Publicado 2014

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours

por Diaz-Padilla, I, Siu, L L, San Pedro-Salcedo, M, Razak, A R A, Colevas, A D, Shepherd, F A, Leighl, N B, Neal, J W, Thibault, A, Liu, L, Lisano, J, Gao, B, Lawson, E B, Wakelee, H A
Publicado 2012